Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2015, Article ID 160835, 11 pages
http://dx.doi.org/10.1155/2015/160835
Review Article

Prognostic Significance of Serum Alkaline Phosphatase Level in Osteosarcoma: A Meta-Analysis of Published Data

Department of Orthopaedics, Second Affiliated Hospital, College of Medicine, Zhejiang University, No. 88, Jiefang Road, Hangzhou 310009, China

Received 16 July 2015; Accepted 12 October 2015

Academic Editor: Dominic Fan

Copyright © 2015 Hai-Yong Ren et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. T. Ta, C. R. Dass, P. F. M. Choong, and D. E. Dunstan, “Osteosarcoma treatment: state of the art,” Cancer and Metastasis Reviews, vol. 28, no. 1-2, pp. 247–263, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. D. C. Dahlin and K. K. Unni, “Osteosarcoma of bone and its important recognizable varieties,” The American Journal of Surgical Pathology, vol. 1, no. 1, pp. 61–72, 1977. View at Publisher · View at Google Scholar · View at Scopus
  3. J. Ritter and S. S. Bielack, “Osteosarcoma,” Annals of Oncology, vol. 21, no. Supplement 7, pp. vii320–vii325, 2010. View at Publisher · View at Google Scholar
  4. L. Mirabello, R. J. Troisi, and S. A. Savage, “Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program,” Cancer, vol. 115, no. 7, pp. 1531–1543, 2009. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Hameed and H. Dorfman, “Primary malignant bone tumors—recent developments,” Seminars in Diagnostic Pathology, vol. 28, no. 1, pp. 86–101, 2011. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Kager, A. Zoubek, U. Pötschger et al., “Primary metastatic osteosarcoma: presentation and outcome of patients treated on neoadjuvant Cooperative Osteosarcoma Study Group protocols,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 2011–2018, 2003. View at Publisher · View at Google Scholar · View at Scopus
  7. S. S. Bielack, B. Kempf-Bielack, G. Delling et al., “Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols,” Journal of Clinical Oncology, vol. 20, no. 3, pp. 776–790, 2002. View at Publisher · View at Google Scholar · View at Scopus
  8. A. J. Chou, D. S. Geller, and R. Gorlick, “Therapy for osteosarcoma: where do we go from here?” Pediatric Drugs, vol. 10, no. 5, pp. 315–327, 2008. View at Publisher · View at Google Scholar · View at Scopus
  9. V. H. C. Bramwell, “Osteosarcomas and other cancers of bone,” Current Opinion in Oncology, vol. 12, no. 4, pp. 330–336, 2000. View at Publisher · View at Google Scholar · View at Scopus
  10. D. S. Geller and R. Gorlick, “Osteosarcoma: a review of diagnosis, management, and treatment strategies,” Clinical Advances in Hematology & Oncology, vol. 8, no. 10, pp. 705–718, 2010. View at Google Scholar · View at Scopus
  11. J. C. Wittig, J. Bickels, D. Priebat et al., “Osteosarcoma: a multidisciplinary approach to diagnosis and treatment,” American Family Physician, vol. 65, no. 6, pp. 1123–1136, 2002. View at Google Scholar · View at Scopus
  12. J. Gill, M. K. Ahluwalia, D. Geller, and R. Gorlick, “New targets and approaches in osteosarcoma,” Pharmacology & Therapeutics, vol. 137, no. 1, pp. 89–99, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. C. Allison, S. C. Carney, E. R. Ahlmann et al., “A meta-analysis of osteosarcoma outcomes in the modern medical era,” Sarcoma, vol. 2012, Article ID 704872, 10 pages, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. M. M. Kaplan, “Alkaline phosphatase,” The New England Journal of Medicine, vol. 286, no. 4, pp. 200–202, 1972. View at Publisher · View at Google Scholar
  15. D. W. Moss, “Perspectives in alkaline phosphatase research,” Clinical Chemistry, vol. 38, no. 12, pp. 2486–2492, 1992. View at Google Scholar · View at Scopus
  16. S. R. Cho, Y. A. Lim, and W. G. Lee, “Unusually high alkaline phosphatase due to intestinal isoenzyme in a healthy adult,” Clinical Chemistry and Laboratory Medicine, vol. 43, no. 11, pp. 1274–1275, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. R. J. McKenna, C. P. Schwinn, K. Y. Soong, and N. L. Higinbotham, “Osteogenic sarcoma arising in Paget's disease,” Cancer, vol. 17, pp. 42–66, 1964. View at Google Scholar · View at Scopus
  18. M. Rauchenzauner, A. Schmid, P. Heinz-Erian et al., “Sex- and age-specific reference curves for serum markers of bone turnover in healthy children from 2 months to 18 years,” The Journal of Clinical Endocrinology and Metabolism, vol. 92, no. 2, pp. 443–449, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. A. Stang, “Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses,” European Journal of Epidemiology, vol. 25, no. 9, pp. 603–605, 2010. View at Publisher · View at Google Scholar · View at Scopus
  20. M. K. B. Parmar, V. Torri, and L. Stewart, “Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints,” Statistics in Medicine, vol. 17, no. 24, pp. 2815–2834, 1998. View at Google Scholar · View at Scopus
  21. R. DerSimonian, “Meta-analysis in the design and monitoring of clinical trials,” Statistics in Medicine, vol. 15, no. 12, pp. 1237–1248, 1996. View at Google Scholar
  22. J. P. T. Higgins, S. G. Thompson, J. J. Deeks, and D. G. Altman, “Measuring inconsistency in meta-analyses,” British Medical Journal, vol. 327, no. 7414, pp. 557–560, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. C. B. Begg and M. Mazumdar, “Operating characteristics of a rank correlation test for publication bias,” Biometrics, vol. 50, no. 4, pp. 1088–1101, 1994. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Bax, N. Ikeda, N. Fukui, Y. Yaju, H. Tsuruta, and K. G. M. Moons, “More than numbers: the power of graphs in meta-analysis,” American Journal of Epidemiology, vol. 169, no. 2, pp. 249–255, 2009. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Aparicio, A. Segura, J. Montalar et al., “Long-term results after combined modality treatment for non-metastatic osteosarcoma,” Medical Oncology, vol. 16, no. 4, pp. 255–260, 1999. View at Publisher · View at Google Scholar · View at Scopus
  26. A. F. Foukas, N. S. Deshmukh, R. J. Grimer, D. C. Mangham, E. G. Mangos, and S. Taylor, “Stage-IIB osteosarcomas around the knee. A study of MMP-9 in surviving tumour cells,” The Journal of Bone and Joint Surgery—British Volume, vol. 84, no. 5, pp. 706–711, 2002. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Ford, A. Saithna, R. J. Grimer, and P. Picci, “Comparison of the outcome of conventional osteosarcoma at two specialist international orthopaedic oncology centres,” Sarcoma, vol. 8, no. 1, pp. 13–18, 2004. View at Publisher · View at Google Scholar · View at Scopus
  28. J. A. M. Bramer, A. A. Abudu, R. M. Tillman, S. R. Carter, V. P. Sumathi, and R. J. Grimer, “Pre- and post-chemotherapy alkaline phosphatase levels as prognostic indicators in adults with localised osteosarcoma,” European Journal of Cancer, vol. 41, no. 18, pp. 2846–2852, 2005. View at Publisher · View at Google Scholar · View at Scopus
  29. V. Mialou, T. Philip, C. Kalifa et al., “Metastatic osteosarcoma at diagnosis: prognostic factors and long-term outcome—the French pediatric experience,” Cancer, vol. 104, no. 5, pp. 1100–1109, 2005. View at Publisher · View at Google Scholar · View at Scopus
  30. B. Yalçın, G. Gedikoğlu, T. Kutluk, A. Varan, C. Akyüz, and M. Büyükpamukçu, “C-erbB-2 expression and prognostic significance in osteosarcoma,” Pediatric Blood — Cancer, vol. 51, no. 2, pp. 222–227, 2008. View at Publisher · View at Google Scholar
  31. A. J. Chou, E. S. Kleinerman, M. D. Krailo et al., “Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children's Oncology Group,” Cancer, vol. 115, no. 22, pp. 5339–5348, 2009. View at Publisher · View at Google Scholar · View at Scopus
  32. C. Kim, E. Shin, S. Hong et al., “Clinical value of ezrin expression in primary osteosarcoma,” Cancer Research and Treatment, vol. 41, no. 3, pp. 138–144, 2009. View at Publisher · View at Google Scholar
  33. P. K. Wu, W. M. Chen, C. F. Chen, O. K. Lee, C. K. Haung, and T. H. Chen, “Primary osteogenic sarcoma with pulmonary metastasis: clinical results and prognostic factors in 91 patients,” Japanese Journal of Clinical Oncology, vol. 39, no. 8, pp. 514–522, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. Y. Yao, Y. Dong, F. Lin et al., “The expression of CRM1 is associated with prognosis in human osteosarcoma,” Oncology Reports, vol. 21, no. 1, pp. 229–235, 2009. View at Publisher · View at Google Scholar · View at Scopus
  35. M. M. Hagleitner, P. M. Hoogerbrugge, W. T. A. van der Graaf, U. Flucke, H. W. B. Schreuder, and D. M. W. M. te Loo, “Age as prognostic factor in patients with osteosarcoma,” Bone, vol. 49, no. 6, pp. 1173–1177, 2011. View at Publisher · View at Google Scholar · View at Scopus
  36. S. Ferrari, P. Ruggieri, G. Cefalo et al., “Neoadjuvant chemotherapy with methotrexate, cisplatin, and doxorubicin with or without ifosfamide in nonmetastatic osteosarcoma of the extremity: an Italian sarcoma group trial ISG/OS-1,” Journal of Clinical Oncology, vol. 30, no. 17, pp. 2112–2118, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Han, B. Yong, C. Luo, P. Tan, T. Peng, and J. Shen, “High serum alkaline phosphatase cooperating with MMP-9 predicts metastasis and poor prognosis in patients with primary osteosarcoma in Southern China,” World Journal of Surgical Oncology, vol. 10, article 37, 2012. View at Publisher · View at Google Scholar · View at Scopus
  38. A. Durnali, N. Alkis, S. Cangur et al., “Prognostic factors for teenage and adult patients with high-grade osteosarcoma: an analysis of 240 patients,” Medical Oncology, vol. 30, no. 3, article 624, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. D. Min, F. Lin, Z. Shen et al., “Analysis of prognostic factors in 333 Chinese patients with high-grade osteosarcoma treated by multidisciplinary combined therapy,” Asia-Pacific Journal of Clinical Oncology, vol. 9, no. 1, pp. 71–79, 2013. View at Publisher · View at Google Scholar · View at Scopus
  40. G. Y. Hung, H. J. Yen, C. C. Yen et al., “Experience of pediatric osteosarcoma of the extremity at a single institution in Taiwan: prognostic factors and impact on survival,” Annals of Surgical Oncology, vol. 22, no. 4, pp. 1080–1087, 2015. View at Publisher · View at Google Scholar
  41. K. Berner, K. S. Hall, O. R. Monge, H. Weedon-Fekjær, O. Zaikova, and Ø. S. Bruland, “Prognostic factors and treatment results of high-grade osteosarcoma in norway: a scope beyond the ‘classical’ patient,” Sarcoma, vol. 2015, Article ID 516843, 14 pages, 2015. View at Publisher · View at Google Scholar
  42. J. A. Lee, D. H. Kim, J. S. Lim et al., “The survival of osteosarcoma patients 10 years old or younger is not worse than the survival of older patients: a retrospective analysis,” Cancer Research and Treatment, vol. 39, no. 4, pp. 160–164, 2007. View at Publisher · View at Google Scholar
  43. G. Bacci, P. Picci, S. Ferrari et al., “Prognostic significance of serum alkaline phosphatase measurements in patients with osteosarcoma treated with adjuvant or neoadjuvant chemotherapy,” Cancer, vol. 71, no. 4, pp. 1224–1230, 1993. View at Google Scholar · View at Scopus
  44. S. Smeland, C. Müller, T. A. Alvegard et al., “Scandinavian Sarcoma Group Osteosarcoma Study SSG VIII: prognostic factors for outcome and the role of replacement salvage chemotherapy for poor histological responders,” European Journal of Cancer, vol. 39, no. 4, pp. 488–494, 2003. View at Publisher · View at Google Scholar · View at Scopus
  45. S. H. Kim, K.-H. Shin, H. Y. Kim et al., “Postoperative nomogram to predict the probability of metastasis in enneking stage IIB extremity osteosarcoma,” BMC Cancer, vol. 14, article 666, 2014. View at Publisher · View at Google Scholar · View at Scopus
  46. F. R. Eilber and E. Caulkins, “Bone tumors—clinical and radiologic investigation,” in Current Concepts of Diagnosis and Treatment of Bone and Soft Tissue Tumors, H. Uhthoff, Ed., pp. 47–54, Springer, Berlin, Germany, 1984. View at Publisher · View at Google Scholar
  47. M. D. Lockshin and I. T. Higgins, “Prognosis in osteogenic sarcoma,” Clinical Orthopaedics and Related Research, vol. 58, pp. 85–103, 1968. View at Google Scholar · View at Scopus
  48. P. E. Scranton Jr., F. A. DeCicco, R. S. Totten, and E. J. Yunis, “Prognostic factors in osteosarcoma. A review of 20 year's experience at the University of Pittsburgh Health Center Hospitals,” Cancer, vol. 36, no. 6, pp. 2179–2191, 1975. View at Publisher · View at Google Scholar · View at Scopus
  49. R. J. Mckenna, C. P. Schwinn, K. Y. Soong, and N. L. Higinbotham, “Sarcomata of the osteogenic series (osteosarcoma, fibrosarcoma, chondrosarcoma, parosteal osteogenic sarcoma, and sarcomata arising in abnormal bone). An analysis of 552 cases,” The Journal of Bone & Joint Surgery—American Volume, vol. 48, no. 1, pp. 1–26, 1966. View at Google Scholar
  50. S. Turan, B. Topcu, I. Gökçe et al., “Serum alkaline phosphatase levels in healthy children and evaluation of alkaline phosphatase z-scores in different types of rickets,” Journal of Clinical Research in Pediatric Endocrinology, vol. 3, no. 1, pp. 7–11, 2011. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Szulc, E. Seeman, and P. D. Delmas, “Biochemical measurements of bone turnover in children and adolescents,” Osteoporosis International, vol. 11, no. 4, pp. 281–294, 2000. View at Publisher · View at Google Scholar · View at Scopus
  52. J. R. Farley, E. Kyeyune-Nyombi, N. M. Tarbaux, S. L. Hall, and D. D. Strong, “Alkaline phosphatase activity from human osteosarcoma cell line SaOS-2: an isoenzyme standard for quantifying skeletal alkaline phosphatase activity in serum,” Clinical Chemistry, vol. 35, no. 2, pp. 223–229, 1989. View at Google Scholar · View at Scopus
  53. C. Pautke, M. Schieker, T. Tischer et al., “Characterization of osteosarcoma cell lines MG-63, Saos-2 and U-2 OS in comparison to human osteoblasts,” Anticancer Research, vol. 24, no. 6, pp. 3743–3748, 2004. View at Google Scholar · View at Scopus
  54. N. N. Ali, M. A. Harrison, J. Rowe, and N. M. Teich, “Spectrum of osteoblastic differentiation in new cell lines derived from spontaneous murine osteosarcomas,” Bone, vol. 14, no. 6, pp. 847–858, 1993. View at Publisher · View at Google Scholar · View at Scopus
  55. G. S. Stein, J. B. Lian, and T. A. Owen, “Relationship of cell growth to the regulation of tissue-specific gene expression during osteoblast differentiation,” The FASEB Journal, vol. 4, no. 13, pp. 3111–3123, 1990. View at Google Scholar · View at Scopus
  56. S. Limmahakhun, P. Pothacharoen, N. Theera-Umpon et al., “Relationships between serum biomarker levels and clinical presentation of human osteosarcomas,” Asian Pacific Journal of Cancer Prevention, vol. 12, no. 7, pp. 1717–1722, 2011. View at Google Scholar · View at Scopus
  57. J. Ambroszkiewicz, J. Gajewska, T. Klepacka, M. Chełchowska, T. Laskowska-Klita, and W. Woźniak, “Clinical utility of biochemical bone turnover markers in children and adolescents with osteosarcoma,” Advances in Medical Sciences, vol. 55, no. 2, pp. 266–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  58. P. P. L. Liu, K. S. Leung, S. M. Kumta, K. M. Lee, and K. P. Fung, “Bone-specific alkaline phosphatase in plasma as tumour marker for osteosarcoma,” Oncology, vol. 53, no. 4, pp. 275–280, 1996. View at Publisher · View at Google Scholar · View at Scopus